Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
Conditions
Cholangiocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda, Bad Liebenwerda, Germany
Contact: Study coordinator (Stephan Kreher, PD Dr. med.)Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany
Contact: Study coordinator (Matthias Raab, Dr.)Onkologisches Versorgungszentrum Berlin MVZ, Berlin, Germany
Contact: Study coordinator (Reinhard Musch)Gemeinschaftspraxis Hämatologie - Onkologie, Dresden, Germany
Contact: Study coordinator (Jens Freiberg-Richter, Dr. med.)Onkozentrum Dresden, Dresden, Germany
Contact: Study coordinator (Steffen Dörfel, Dr. med.)Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen, Germany
Contact: Study coordinator (Ilektra-Antonia Mavroeidi, Dr. med.)Onkologie Hannover, Hanover, Germany
Contact: Study coordinator (Haytham Kamal, Dr. med.)Onkologie Hof, Hof, Germany
Contact: Study coordinator (Markus Kapp, Dr. med.)Medizinisches Versorgungszentrum Mönchengladbach, Mönchengladbach, Germany
Contact: Study coordinator (Ludger Sellmann, PD Dr. med.)TUM Klinikum Rechts der Isar, Klinik und Poliklinik für Innere Medizin II, München, Germany
Contact: Study coordinator (Sebastian Lange, Dr. med.)Gemeinschaftspraxis für Internistische Onkologie und Hämatologie, Rheine, Germany
Contact: Study coordinator (Almut Berkemeier, Dr. med.)RoMed Klinikum Rosenheim, Hämatologie und Onkologie, Rosenheim, Germany
Contact: Study coordinator (Ulrike Kolar-Michaelis, Dr. med.)ze:roPRAXEN MVZ für Innere Medizin, Weinheim, Germany
Contact: Study coordinator (Manuel Zink, Dr. med.)